These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38742898)

  • 1. Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists.
    Klonoff DC; Kim SH; Galindo RJ; Joseph JI; Garrett V; Gombar S; Aaron RE; Tian T; Kerr D
    Diabetes Obes Metab; 2024 Aug; 26(8):3128-3136. PubMed ID: 38742898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
    Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
    Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.
    Driessen JH; Henry RM; van Onzenoort HA; Lalmohamed A; Burden AM; Prieto-Alhambra D; Neef C; Leufkens HG; de Vries F
    Calcif Tissue Int; 2015 Aug; 97(2):104-12. PubMed ID: 25894068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.
    Dotan I; Rudman Y; Turjeman A; Akirov A; Steinmetz T; Calvarysky B; Diker Cohen T
    Transplantation; 2024 Jul; 108(7):e121-e128. PubMed ID: 38361246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study.
    Garza K; Aminpour E; Shah J; Mehta B; Early D; Gyawali CP; Kushnir V
    Am J Gastroenterol; 2024 Jun; 119(6):1081-1088. PubMed ID: 38534127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services.
    Dao K; Shechtman S; Weber-Schoendorfer C; Diav-Citrin O; Murad RH; Berlin M; Hazan A; Richardson JL; Eleftheriou G; Rousson V; Diezi L; Haefliger D; Simões-Wüst AP; Addor MC; Baud D; Lamine F; Panchaud A; Buclin T; Girardin FR; Winterfeld U
    BMJ Open; 2024 Apr; 14(4):e083550. PubMed ID: 38663923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.
    Gorgojo-Martínez JJ; Serrano-Moreno C; Sanz-Velasco A; Feo-Ortega G; Almodóvar-Ruiz F
    Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):129-137. PubMed ID: 28077257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safe Continuation of Glucagon-like Peptide 1 Receptor Agonists at Endoscopy: A Case Series of 57 Adults Undergoing Endoscopic Sleeve Gastroplasty.
    Maselli DB; Lee D; Bi D; Jirapinyo P; Thompson CC; Donnangelo LL; McGowan CE
    Obes Surg; 2024 Jul; 34(7):2369-2374. PubMed ID: 38753265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to GLP1-RA and SGLT2-I affects clinical outcomes and costs in patients with type 2 diabetes.
    Ciardullo S; Savaré L; Rea F; Perseghin G; Corrao G
    Diabetes Metab Res Rev; 2024 May; 40(4):e3791. PubMed ID: 38549238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
    Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
    Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
    Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
    BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications.
    Dixit AA; Bateman BT; Hawn MT; Odden MC; Sun EC
    JAMA; 2024 May; 331(19):1672-1673. PubMed ID: 38648036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
    Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.
    Fu EL; Clase CM; Janse RJ; Lindholm B; Dekker FW; Jardine MJ; Carrero JJ
    Int J Cardiol; 2022 Apr; 352():172-179. PubMed ID: 35074492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
    Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
    Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
    Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
    J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Mar; 161():108087. PubMed ID: 32084455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.